Skip to Content
Merck
All Photos(1)

Key Documents

SBR00023

Sigma-Aldrich

1-Cyano-4-dimethylaminopyridinium tetrafluoroborate Ready Made Solution

organic cyanylating reagent, 100 mg/mL in acetonitrile

Synonym(s):

4-(dimethylamino)pyridin-1-ium-1-carbonitrile tetrafluoroborate, CDAP

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C8H10BF4N3
CAS Number:
Molecular Weight:
234.99
UNSPSC Code:
12161902
NACRES:
NA.28

biological source

synthetic

Assay

≥97%

form

liquid

mol wt

234.99

concentration

100 mg/mL in acetonitrile

shipped in

dry ice

storage temp.

−20°C

InChI

1S/C8H10N3.BF4/c1-10(2)8-3-5-11(7-9)6-4-8;2-1(3,4)5/h3-6H,1-2H3;/q+1;-1

InChI key

MBLVMDCQDCVKNE-UHFFFAOYSA-N

General description

1-Cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) is crucial in vaccine and biochemical research. It rapidly activates polysaccharides, like TI-2 antigens, in a short time. Further, CDAP enables protein conjugation, vital for creating conjugate vaccines that enhance immune responses. CDAP works effectively at both pH 9-10 and mild alkaline conditions (pH 7-9), making it versatile for various antigens. CDAP′s efficacy in inducing high antibody levels makes it invaluable for developing effective vaccines and immunological reagents.

Application

1-Cyano-4-dimethylamino pyridinium tetrafluoroborate can be used in vaccine research for the conjugation of polysaccharides with proteins

Biochem/physiol Actions

CDAP is a cyanylation reagent for protein sulfhydryl groups which is used to prepare protein-polysaccharide conjugates. CDAP is also an activating agent for polysaccharide resins and is used for the conjugation of lipopolysaccharides while retaining their endotoxic activity.

CDAP is considered to be a less toxic reagent as compared to cyanogen bromide (CNBr) (a known polysaccharides activator). In addition, CDAP is easier to use as it can be employed at a lower pH and has fewer side reactions. It is known that CDAP polysaccharide activation efficiency is optimal at pH 9-10. It was also reported that direct conjugation of protein to CDAP-activated polysaccharides can be performed under mildly alkaline conditions (pH 7-9). It has also been reported that proteins could also be conjugated to CDAP-activated polysaccharides at pH 5.

Features and Benefits

  • Readily available solution, that reduces the need for preparation time
  • Versatile and adaptable for vaccine and biochemical research

Preparation Note

Polysaccharide conjugation: CDAP Ready Made Solution (100mg/mL in acetonitrile) should be added in a ratio of 1mg CDAP to 1mg polysaccharide while vortexing (Example: per 1mg polysaccharide add 10μL of CDAP Ready Made Solution). Add 0.2M triethylamine, 10μL per 1mg polysaccharide to raise the pH of the reaction.

Other Notes

For additional information on our range of Biochemicals, please complete this form.

Pictograms

FlameExclamation mark

Signal Word

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2 - Skin Irrit. 2

Storage Class Code

3 - Flammable liquids

WGK

WGK 3

Flash Point(F)

35.6 °F

Flash Point(C)

2 °C


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

An O-Specific Polysaccharide/Tetanus Toxoid Conjugate Vaccine Induces Protection in Guinea Pigs against Virulent Challenge with Coxiella burnetii
Graves SR. et al.
Vaccines, 10, 1393-1393 (2022)
Carl E Frasch
Vaccine, 27(46), 6468-6470 (2009-06-27)
A conjugate can be a polysaccharide (PS) covalently attached to a protein, which provides T cell epitopes for a normally T cell independent antigen. To produce a conjugate vaccine, the purified PS must first be chemically modified to generate reactive
Carbohydrate-Based Vaccines and Immunotherapies
Guo, Z., & Boons, G.J. et al.
Carbohydrate-Based Vaccines and Immunotherapies, 8 (2009)
D E Shafer et al.
Vaccine, 18(13), 1273-1281 (2000-01-29)
Covalently linking protein to polysaccharides converts the anti-polysaccharide immune response from a T-cell independent response to one which is T-cell dependent. The organic cyanylating reagent 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) (Vaccine 14:190, 1996) has been used to activate polysaccharides, which can then
A Lees et al.
Vaccine, 14(3), 190-198 (1996-02-01)
Neonates have poor immune responses to type 2 T-cell independent antigens (TI-2), such as polysaccharides and immunization of human infants with these antigens does not induce protective levels of serum antibodies. Conjugating proteins to TI-2 antigens converts the immune response

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service